Recent approaches for studying the role of Glia

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 1, 2014, Pages 52-62

  Park, Seyeon ^a  

^a Dongduk Women's University   (South Korea)

Author keywords

G protein coupled receptors; Glial cells; Gq DREADD (designer receptor exclusively activated by designer drug); Neuronal disorder; Proteomics; Tissue culture

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE A2A RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHOLINERGIC RECEPTOR; DOPAMINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTAMINE RECEPTOR; INOSITOL 1, 4, 5 TRISPHOSPHATE RECEPTOR; LEVODOPA; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 3; OPIATE RECEPTOR; PROTEIN S100B; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y RECEPTOR; SEROTONIN RECEPTOR; SNARE PROTEIN; TACHYKININ RECEPTOR; UNCLASSIFIED DRUG;

ADDICTION; ALZHEIMER DISEASE; ARTICLE; BIOINFORMATICS; CELL FUNCTION; EPILEPSY; GENOMICS; GLIA; GLIA CELL; HUMAN; MOOD DISORDER; NERVOUS SYSTEM FUNCTION; NONHUMAN; PAIN; PARKINSON DISEASE; PROTEOMICS; SCHIZOPHRENIA;

ANIMALS; BRAIN DISEASES; COMPUTATIONAL BIOLOGY; GENOMICS; HUMANS; NERVE TISSUE PROTEINS; NEUROGLIA; PROTEOMICS; RECEPTORS, CELL SURFACE;

EID: 84896729996     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660191     Document Type: Article

References (202)

1. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FMV. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 2007; 10(12): 1538-1543.
2. McMahon SB, Malcangio M. Current Challenges in Glia-Pain Biology. Neuron 2009: 64(1): 46-54.
3. Rossi DJ, Brady JD, Mohr C. Astrocyte metabolism and signaling during brain ischemia. Nat Neurosci 2007; 10: 1377-1386.
4. Rajkowska G. Dysfunction in neural circuits involved in the pathophysiology of mood disorders: postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000; 48(8): 766-777.
5. Schroeter ML, Abdul-Khaliq H, Sacher J, et al. Mood Disorders Are Glial Disorders: Evidence from In Vivo Studies. Cardiovasc Psychiatry Neurol 2010; Article ID 780645: 7.
6. Johnston-Wilson NL, Sims CD, Hofmann JP, et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. Mol Psychiatry 2000; 5: 142-149.
7. Miguel-Hidalgo JJ, Baucom C, Dilley G, et al. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry 2000: 48(8): 861-873.
8. Si X, Miguel-Hidalgo JJ, O'Dwyer G, Stockmeier CA, Rajkowska G. Age-dependent eductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacol 2004; 29(11): 2088-2096.
9. Webster MJ, Johnston-Wislon N, Nagata K, Yolken RH. Alterations in the expression of phosphorylated glial fibrillary acidic proteins in the frontal cortex of individuals with schizophrenia, bipolar disorder, and depression. Schizophr Res 2000; 41: 106.
10. Hamidi M, Drevets WC, Price JL. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry 2004; 55(6): 563-569.
11. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 2004; 67(2): 269-275.
12. Vostrikov VM, Uranova NA, Orlovskaya DD. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 2007; 94(1): 273-280.
13. Cotter DR, Pariante CM, Everall IP. Glial cell abnormalities inmajor psychiatric disorders: the evidence and implications. Brain Res Bull 2001; 55(5): 585-595.
14. Harrison PJ. The neuropathology of primary mood disorder. Brain 2002; 125(7): 1428-1449.
15. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression CNS Neurol Disord Drug Targets 2007; 6(3): 219-233.
16. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiat 2001; 58(6): 545-553.
17. Ongür D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95(22): 13290-13295.
18. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45(9): 1085-1098.
19. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood isorders. Mol Psychiatry 2000; 5(6): 578-593.
20. Rothermundt M, Ahn JN, Entrich K, Griese N, Jorgens S. Glial Activation in Schizophrenia - Evidence from Clinical Studies. Eur Psychiatric Rev 2010; 3(2): 14-17.
21. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49(1-2): 1-52.
22. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999; 122(4): 593-624.
23. Powers RE. The neuropathology of schizophrenia. J Neuropathol Exp Neurol 1999; 58(7): 679-690.
24. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: A circuit based model of schizophrenia. Biol Psychiatry 1999; 45: 17-25.
25. McGlashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity Arch Gen Psychiatry 2000; 57(7): 637-648.
26. Jones LB, Johnson N, Byne W. Alterations in MAP2 immunocytochemistry in areas 9 and 32 of schizophrenic prefrontal cortex. Psychiatry Res Neuroimaging 2002; 114(3): 137-148.
27. Danos P, Schmidt A, Baumann B, et al. Volume and neuron number of the mediodorsal thalamic nucleus in schizophrenia: a replication study. Psychiatry Res Neuroimaging 2005; 140(3): 281-289.
28. Czéch B, Simon M, Schmelting B, Hiemke C, Fuchs E. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsycho-pharmacology 2006; 31: 1616-1626.
29. Arnold SE, Trojanowski JQ, Gur RE, et al. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry 1998; 55(3): 225-232.
30. Arnold SE. Neurodevelopmental abnormalities in schizophrenia: Insights from neuropathology. Dev Psychopathol 1999; 11: 439-456.
31. Falkai P, Honer WG, David S, et al. No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study. Neuropath Appl Neurol 1999; 25(1): 48-53.
32. Webster MJ, Knable MB, Johnston-Wilson, Nagata N, Yolken RH. Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia. bipolar disorder, and depression. Brain Behav Immun 2001; 15(4): 388-400.
33. Steffek AE, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr Res 2008; 103(1-3): 71-82.
34. Rajkowska G, Miguel-Hidalgo JJ, Makkos Z, et al. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr Res 2002; 57(2-3): 127-138.
35. Steiner J, Bernstein HG, Bielau H, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 2007; 8: 2.
36. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. Serum markers support disease-specific glial pathology in major depression. J Affect Disorders 2008; 111(2-3): 271-280.
37. Schroeter ML, Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009; 14: 235-237.
38. Raponi E, Agenes F, Delphin C, et al. S100B expression defines a state in which GFAP-expressing cells lose their neural stem cell potential and acquire a more mature developmental stage. Glia 2007; 55(2): 165-177.
39. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium- dependent and -independent interactions of the S100 protein family. Biochem J 2006; 396(2): 201-214.
40. Scḧafer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996; 21(4): 134-140.
41. Schroeter ML, Abdul-Khaliq H, Frühauf S, et al. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res 2003; 62(3): 231-236.
42. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995; 37(4): 417-429.
43. Pinto SS, Gottfried C, Mendez A, Gonçalves D, et al. Wofchuk S, Rodnight R. Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology. FEBS Lett 2000; 486(3): 203-207.
44. Dean B, Gray L, Scarr E. Regionally specific changes in levels of cortical S100β in bipolar 1 disorder but not Schizophrenia. Aust NZ J Psychiat 2006; 40(3): 217-224.
45. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and qualityof-life issues. Mayo Clin Proc 2006; 81: S3-S11.
46. Christo PJ, Mazloomdoost D. Cancer pain and analgesia Ann NY Acad Sci 2008; 1138: 278-298.
47. Douglas C, Wollin JA, Windsor C. Illness and demographic correlates of chronic pain among a communitybased sample of people with multiple sclerosis. Arch Phys Med Rehab 2008; 89(10): 1923-1932.
48. Russell AS. Quality-of-life assessment in rheumatoid arthritis. Pharmacoeconomics 2008; 26: 831-846.
49. Winter Y, Schepelmann K, Spottke AE, et al. Health related quality of life in ALS, myasthenia gravis and facioscapulohumeralmuscular dystrophy. J Neurol 2010; 257: 1473-1481.
50. Gosselin RD, Suter MR, Ji RR, Decosterd L. Glial Cells and Chronic Pain Romain. Neuroscientist 2010; 16(5): 519-531.
51. Ren K, Dubner R. Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Curr Opin Anaesthesiol 2008; 21(5): 570-579.
52. Coyle DE. Partial peripheral nerve injury leads to activation of astroglia and microglia which parallels the development of allodynic behavior. Glia 1998; 23(1): 75-83.
53. Zhuang ZY, Gerner P, Woolf CJ, Ji RR. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005; 114(1-2): 149-159.
54. Mantyh PW. Neurobiology of substance P and the NK1 receptor. J Clin Psychiatry 2002; 63(11): 6-10.
55. Malmberg AB, Yaksh TL. Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test in rats. Pain 1993: 54(3): 291-300.
56. Sergeyev V, Fetissov S, Mathe AA, et al. Neuropeptide expression in rats exposed to chronic mild stresses. Psychopharmacology 2005; 178(2-3): 115-124.
57. Rasley A, Bost KL, Olson JK, Miller SD, Marriott I. Expression of functional NK-1 receptors in murine microglia. Glia 2002: 37(3): 258-267.
58. Marriott DR, Wilkin GP, Wood JN. Substance P-induced release of prostaglandins from astrocytes: regional specialisation and correlation with phosphoinositol metabolism. J Neurochem 1991; 56(1): 259-265.
59. Tanaka K, Watase K, Manabe T, et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 1997; 276(5319): 1699-1702.
60. Bradesi S. Role of spinal cord glia in the central processing of peripheral pain perception. Neurogastroenterol Motil 2010; 22(5): 499-511.
61. Stone LC, Molliver DC. In Search of Analgesia: Emerging Roles of GPCRs in Pain. Mol Interv 2009; 9(5): 234-251.
62. Tanaka T, Minami M, Nakagawa T, Satoh M. Enhanced production of monocyte chemoattractant protein-1 in the dorsal root ganglia in a rat model of neuropathic pain: possible involvement in the development of neuropathic pain. Neurosci Res 2004; 48(4): 463-469.
63. Bradesi S, Svensson CI, Steinauer J, et al. Role of spinal microglia in visceral hyperalgesia and NK1R up-regulation in a rat model of chronic stress. Gastroenterology 2009; 136(4): 1339-1348.
64. Inoue K. ATP receptors of microglia involved in pain. Novartis Found Symp 2006; 276: 263-272.
65. Zhuang ZY, Kawasaki Y, Tan PH, et al. Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injuryinduced cleavage of fractalkine. Brain Behav Immun 2007; 21(5): 642-651.
66. Ji RR, Kawasaki Y, Zhuang ZY, Wen YR, Zhang YQ. Protein kinases as potential targets for the treatment of pathological pain. Handb Exp Pharmacol 2007; 177: 359-389.
67. Jin SX, Zhuang ZY, Woolf CJ, Ji RR. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 2003; 23(10): 4017-4022.
68. Korolainen MA, Nyman TA, Aittokallio T, Pirttila T. An update on clinical proteomics in Alzheimer's research. J Neurochem 2010; 112(6): 1386-1414.
69. Keller JN. Age-related neuropathology, cognitive decline, and Alzheimer's disease. Ageing Res Rev 2006; 5(1): 1-13.
70. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69(24): 2197-2204.
71. Altar CA, Vawter MP, Ginsberg SD. Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology 2009; 34: 18-54.
72. Paschen W. Role of calcium in neuronal cell injury: which subcellular compartment is involved? Brain Res Bull 2000; 53(4): 409-413.
73. Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr 2005; 827(1): 65-75.
74. Pereira C, Agostinho P, Moreira PI, Cardoso S, Oliveira CR. Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr Drug Targets CNS Neurol Disord 2005; 4: 383-403.
75. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007; 184(1-2): 69-91.
76. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 2008; 104(6): 1433-1439.
77. Griffin, WST, Sheng JG, Royston MC, et al. Glial-neuronal interactions in Alzheimer's disease: the potential role of a "cytokine cycle" in disease progression. Brain Pathol 1998; 8(1): 65-72.
78. Skaper SD. The Brain as a Target for Inflammatory Processes and Neuroprotective Strategies. Ann NY Acad Sci 2007; 1122: 23-34.
79. Craft JM, Watterson DM, Van Eldik LJ. Neuroinflammation: a potential therapeutic target. Expert Opin Ther Targets 2005; 9(5): 887-900.
80. Akiyama H, Bargera S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2003; 21(3): 383-421.
81. Mcgeer PL, Mcgeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 2001; 22(6): 799-809.
82. Eikelenboom P, Bate C, Van Gool WA, et al. Neuroinflammation in Alzheimer's disease and prion disease. GLIA 2002; 40(2): 232-239.
83. Parvathenani LK, Tertyshnikova S, Greco CR, et al. P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem 2003; 278: 13309-13317.
84. Skaper SD, Facci L, Culbert AA, et al. P2X7 receptors on microglial cells mediate injury to cortical neurons in vitro. GLIA 2006; 54(3): 234-242.
85. Culbert AA, Skaper SD, Howlett DR, et al. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic model of Alzheimer disease. J Biol Chem 2006; 281: 23658-23667.
86. Golde S, Chandran S, Brown GC, Compston, A. Different pathways for iNOSmediated toxicity in vitro dependent on neuronal maturation and NMDAreceptor expression. J Neurochem 2002; 82(2): 269-282.
87. Diemel LT, Copelman CA, Cuzner ML. Macrophages in CNS remyelination: friend or foe? Neurochem Res 1998; 23(3): 341-347.
88. Giulian D. Microglia and the immune pathology of Alzheimer disease. Am J Hum Gen 1999; 65(1): 13-18.
89. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001; 410(6831): 988-994.
90. Douglas F, Geoffrey B. Purinergic signalling in neuron-glia interactions Nat Rev Neurosci 2006; 7: 423-436.
91. Morigiwa K, Quan MZ, Murakami M, et al. P2 purinoceptor expression and functional changes of hypoxia-activated cultured rat retinal microglia. Neurosci Lett 2000; 282(3): 153-156.
92. Franke H, Gunther A, Grosche J, et al. P2X7 receptor expression after ischemia in the cerebral cortex of rats. J Neuropathol Exp Neurol 2004; 63(7): 686-699.
93. Narcisse L, Scemes E, Zhao Y, Lee SC, Brosnan, CF. The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes. Glia 2005; 49(2): 245-258.
94. Volante C, Amadio S, Cavaliere F, et al. Extracellular ATP and neurodegeneration. CNS Neurol Disord Drug Targets 2003: 2(6): 403-412.
95. Honda S, Sasaki Y, Ohsawa K, et al. Extracellular ATP and ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors. J Neurosci 2001; 21(6): 1975-1982.
96. Verderio C, Matteoli M. ATP mediates calcium signalling between astrocytes and microglial cells: modulation by IFN-gamma. J Immuol 2001; 166(10): 6383-6891.
97. Keane RW, Davis AR, Dietrich WD. Inflammatory and apoptotic signaling after spinal cord injury. J Neurotrauma 2006; 23(3-4): 335-344.
98. Moatassim EL, Dubyak C, Dubyak GR. A novel pathway for the activation of phospholipase D by P2Z purinergic receptors in BAC1.2F5 macrophages. J Biol Chem 1992; 267 23664-23673.
99. Murgia M, Hanau S, Pizzo P, Rippa M, Virgilio FD. Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor. J Biol Chem 1993; 268 8199-8203.
100. Nuttle LC, Dubyak GR. Differential activation of cation channels and non-selective pores by macrophage P2Z purinergic receptors expressed in Xenopus oocytes. J Biol Chem 1994; 269 13988-13996.
101. Pisani A, Bonsi P, Centonze D, et al. Targeting striatal cholinergic interneurons in Parkinson's disease: focus on metabotropic glutamate receptors. Neuropharmacology 2003; 45(1): 45-56.
102. Hirono M, Yoshioka T, Konishi S. GABA(B) receptor activation enhances mGluRmediated responses at cerebellar excitatory synapses. Nat Neurosci 2001; 4(12): 1207-1216.
103. Fellin T, Carmignoto G. Neurone-to-astrocyte signalling in the brain represents a distinct multifunctional unit. J Physiol 2004; 559(1): 3-15.
104. Pasti L, Volterra A, Pozzan T, Carmignoto G. Intracellular calcium oscillations in astrocytes: A highly plastic, bidirectional form of communication between neurons and astrocytes in situ. J Neurosci 1997; 17(20): 7817-7830.
105. Perea G, Araque A. Properties of synaptically evoked astrocyte calcium signal reveal synaptic information processing by astrocytes. J Neurosci 2005; 25(9): 2192-2203.
106. Porter JT, McCarthy KD. Hippocampal astrocytes in situ respond to glutamate released from synaptic terminals. J Neurosci 1996; 16(16): 5073-5081.
107. Kang J, Jiang L, Goldman SA, Nedergaard M. Astrocytemediated potentiation of inhibitory synaptic transmission. Nat Neurosci 1998; 1: 683-692.
108. Araque A, Martin ED, Perea G, Arellano JI, Buno W. Synaptically released acetylcholine evokes Ca2+ elevations in astrocytes in hippocampal slices. J Neurosci 2002; 22(7): 2443-2450.
109. Navarrete M, Araque A. Endocannabinoids mediate neuronastrocyte communication. Neuron 2008; 57(6): 883-893.
110. Fahn S. How do you treat motor complications in Parkinson's disease: medicine, surgery, or both? Ann Neurol 2008; 64(Suppl. 2): S56-S64.
111. Svenningsson P, Le Moine C, Fisone G, Fredholm BB. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 1999; 59(4): 355-396.
112. Hettinger BD, Lee A, Linden J, Rosin DL. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 2001; 431(3): 331-346.
113. Boison D, Chen JF, Fredholm BB. Adenosine Signaling and function in glial cell. Cell Death Dis 2010; 17: 1071-1082.
114. Boison D. The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 2008; 84(3): 249-262.
115. Tian GF, Azmi H, Takano T, et al. An astrocytic basis of epilepsy. Nature Med 2005; 11 973-981.
116. Binder DK, Steinhauser C. Functional changes in astroglial cells in epilepsy. Glia 2006; 54(5): 358-368.
117. Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: an overview. Trends Neurosci 2009; 32(1): 19-29.
118. Li T, Lan JQ, Fredholm BB, Simon RP, Boison D. Adenosine dysfunction in astrogliosis: cause for seizure generation? Neuron Glia Biol 2007; 3(4): 353-366.
119. Stewart G, Kniazeff J, Prezeau L, et al. Metabotropic Receptors for Glutamate and GABA, Pharmacology. In: Gallelli L, Ed. Pharmacology, Toxicology and Pharmaceutical Science; 2012; pp. 1-41.
120. Bowers MS, McFarland K, Lake RW, et al. Activator of G protein signaling 3: a gatekeeper of cocaine sensitization and drug seeking. Neuron 2004; 42(2): 269-281.
121. Kenny PJ, Markou A. The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci 2004; 25(5): 265-272.
122. Neugebauer V, Zinebi F, Russell R, Gallagher JP, Shinnick-Gallagher P. Cocaine and kindling alter the sensitivity of group II and III metabotropic glutamate receptors in the central amygdala. J Neurphysiol 2000; 84(2): 759-770.
123. Ghasemzadeh MB, Mueller C, Vasudevan P. Behavioral sensitization to cocaine is associated with increased glutamate receptor trafficking to the postsynaptic density after extended withdrawal period. Neuroscience 2009; 159(1): 414-426.
124. Hansson E, Rönnbäck L. Astrocytic Receptors and second messenger systems. Adv Mol Cell Biol 2006; 31: 475-501.
125. Pascual O, Casper KB, Kubera C, et al. Astrocytic purinergic signaling coordinates synaptic networks. Science 2005; 310(5745): 113-116.
126. Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA 2007; 104(12): 5163-5168.
127. Dong S, Rogan SC, Roth BL. Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs. Nat Protoc 2010; 5: 561-573.
128. Pei Y, Rogan SC, Yan F, Roth BL. Engineered GPCRs as tools to modulate signal transduction. Physiology 2008; 23(6): 313-321.
129. Nichols CD, Roth BL. Engineered G-protein Coupled Receptors are Powerful Tools to Investigate Biological Processes and Behaviors. Front Mol Neurosci 2009; 2: 16.
130. Alexander GM, Rogan SC, Abbas AI, et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 2009; 63(1): 27-39.
131. Krashes MJ, Koda S, Ye CP, et al. Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. J Clin Invest 2011; 121(4): 1424-1428.
132. Guettier JM, Gautam D, Scarselli M, et al. A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci USA 2009; 106(45): 19197-19202.
133. Rogan SC, Roth BL. Remote control of neuronal signaling. Pharmacol Rev 2011; 63(2): 291-315.
134. 2+ signaling. Science 2010; 327(5970): 1250-1254.
135. Fiacco TA, Agulhon C, Taves SR, et al. Selective stimulation of astrocyte calcium in situ does not affect neuronal excitatory synaptic activity. Neuron 2007; 54(4): 611-626.
136. 2+ signaling is abolished in atrial myocytes of inositol-1: 4: 5-trisphosphate(IP3)-receptor type 2-deficient mice. Circ Res 2005; 96: 1274-1281.
137. 2+ signaling is abolished in atrial myocytes of inositol-1: 4: 5-trisphosphate(IP3)-receptor type 2-deficient mice. Circ Res 2005; 96: 1274-1281.
138. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006; 52(1): 39-59.
139. Bastrikova N, Garder GA, Reece JM, Jeromin A, Dudek SM. Synapse elimination accompanies functional plasticity in hippocampal neurons. Proc Natl Aad Sci USA 2008; 105(8): 3123-3127.
140. Gahwiler BH, Capogna M, Debanne D, Mckinney RA, Thompson SM. Organotypic slice culture: a technique has come of age. Trends Neurosci 1997; 20(10): 471-477.
141. Simoni AD, Yu LM. Preparation of organotypic hippocampal slice cultures: interface method. Nat Protoc 2006; 2: 1439-1445.
142. Smith K. Settling the great glia debate. Nature 2010; 468(7321): 160-162.
143. Park S. Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders. Curr Pharmacogenom Personal Med 2011; 9(2): 102-122.
144. Skorobogatko YV, Deuso J, Adolf-Bergfoyle J, et al. Human Alzheimer's disease synaptic O-GlcNAc site mapping and iTRAQ expression proteomics with ion trap mass spectrometry. Amino Acids 2011; 40(3): 765-779.
145. Waragai M, Wei J, Fujita M, et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 2006; 345(3): 967-972.
146. Basso M, Giraudo S, Corpillo D, et al. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004; 4(12): 3943-3952.
147. Huang JT, Wang L, Prabakaran S, et al. Independent proteinprofiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry 2008; 13(12): 1118-1128.
148. Levin Y, Wang L, Schwarz E, et al. Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol Psychiatry 2010; 15: 1088-1100.
149. Prabakaran S, Wengenroth M, Lockstone HE, et al. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res 2007; 6(1): 141-149.
150. Tamminga CA, Thaker GK, Buchanan R, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992; 49(7): 522-530.
151. English JA, Dicker P, Föcking M, Dunn MJ, Cotter DR. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 2009; 9(12): 3368-3382.
152. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291(5507): 1304-1351.
153. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 1995; 80: 225-236.
154. McCarthy KD, Enkvist K, Shao Y. Astroglial adrenergic receptors: expression and function. Kettenmann H, Ransom BR, Eds.: Neuroglia. Oxford University Press, Oxford 1995; pp. 354-366.
155. Verkhratsky A, Orkand RK, Kettenmann H. Glial calcium: homeostasis and signaling function. Physiol Rev 1998; 78(1): 99-141.
156. Murphy S, Pearce B, Morrow C. Astrocytes have both M1 and M2 muscarinic receptor subtypes. Brain Res 1986; 364(1): 177-180.
157. Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM. Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 1996; 14(1): 35-46.
158. 2+ responses in rat primary astrocyte cultures. J Neurosci Res 1993; 35(3): 246-256.
159. Hagberg GB, Blomstrand F, Nilson M, Tamir H, Hansson E. Stimulation of 5-HT2A receptors on astrocytes in primary culture opens voltage-independent Ca2{thorn} channels. Neurochem Int 1997; 32(2): 153-62.
160. Nilsson M, Hansson E, Rönnbäck L. Adrenergic and 5-HT2 receptors on the same astroglial cell. A microspectrofluorimetric study on cytosolic Ca2{thorn} responses in single cells in primary culture. Dev Brain Res 1991; 63(1-2): 33-41.
161. Hirst W, Cheung NY, Rattray M, Price GW, Wilkin GP. Cultured astrocytes express messenger RNA for multiple serotonin receptor subtypes, without functional coupling of 5-HT1 receptor subtypes to adenyl cyclase. Mol Brain Res 1998; 61(1-2): 90-99.
162. Kong, EKC, Peng L, Chen Y, et al. Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochem Res 2002; 27(1-2): 113-120.
163. Sandén N, Thorlin T, Blomstrand F, Persson, PAI, Hansson E. 5-Hydroxytryptamine receptors stimulate Ca2{thorn} increases in cultured astrocytes from three different brain regions Neurochem Int 2000; 36(4-5): 427-434.
164. Carson MJ, Thomas EA, Danielson PE, Sutcliffe JG. The 5-HT5A serotonin receptor is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: a mechanism for neuronal suppression of reactive astrocytes. Glia 1996; 17(4): 317-326.
165. Hirst WD, Price GW, Rattray M, Wilkin GP. Identification of 5-hydroxytryptamine receptors positively coupled to adenyl cyclase in rat cultured astrocytes. Br J Pharmacol 1997; 120(3): 509-515.
166. Hosli L, Hosli E, Schneider U, Wiget W. Evidence for the existence of histamine H1- and H2-receptors on astrocytes of cultured rat central nervous system. Neurosci Lett 1984; 48(3): 287-291.
167. Carman-Krzan M, Lipnik-Stangelj M. Molecular properties of central and peripheral histamine H1 and H2 receptors. Pflugers Arch 2000; 439(7): R131-R132.
168. Inagaki N, Wada H. Histamine and prostanoid receptors on glial cells. Glia 1994; 11(2): 102-109.
169. Juric DM, Male T, Carman-Krzan M. Involvement of histaminergic receptor mechanisms in the stimulation of NT-3 synthesis in astrocytes. Neuropharmacology 2011; 60(7-8): 1309-1317.
170. Zanassi P, Paolillo M, Montecucco A, Avvedimento EV, Schinelli S. Pharmacological and molecular evidence for dopamine D1 receptor expression by striatal astrocytes in culture. J Neurosci Res 1999; 58(4): 544-552.
171. Bal A, Bachelot T, Savasta M, et al. Evidence for dopamine D2 receptor mRNA expression by striatal astrocytes in culture: in situ hybridization and polymerase chain reaction studies. Mol Brain Res 1994; 23(3): 204-212.
172. Miyazaki I, Asanuma M, Diaz-Corrales FJ, Miyoshi K, Ogawa N. Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia. Brain Res 2004; 1029(1): 120-123.
173. Oka M, Wada M, Wu Q, Yamamoto A, Fujita T. Functional expression of metabotropic GABAB receptors in primary cultures of astrocytes from rat cerebral cortex q. Biochem Biophys Res Commun 2006; 341(3): 874-881.
174. Silva GA, Theriault E, Millsa LR, Pennefather PS, Feeney CJ. Group I and II metabotropic glutamate receptor expression in cultured rat spinal cord astrocytes. Neurosci Lett 1999; 263(2-3): 117-120.
175. D'Antoni S, Berretta A, Bonaccorso CM, et al. Metabotropic Glutamate Receptors in Glial Cells. Neurochem Res 2008; 33(12): 2436-2443.
176. Ohishi H, Shigemoto R, Nakanishi S, Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J Comp Neurol 1993; 335(2): 252-260.
177. Schools GP, Kimelberg HK. mGluR3 and mGluR5 are the predominant metabotropic glutamate receptor mRNAs expressed in hippocampal astrocytes acutely isolated from young rats. J Neurosci Res 1999; 58(4): 533-543.
178. Fotuhi M, Standaert DG, Testa CM, Penney JB, Young AB. Differential expression of metabotropic glutamate receptors in the hippocampus and entorhinal cortex of the rat. Mol Brain Res 1994; 21(3-4): 283-292.
179. Mudó G, Trovaro-Salinaro A, Caniglia G, Cheng Q, Condorelli, DF. Cellular localization of mGluR3 and mGluR5 mRNAs in normal and injured rat brain. Brain Res 2007; 1149: 1-13.
180. Besong G, Battaglia G, D'Onofrio M. Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures. J Neurosci 2002; 22(13): 5403-5411.
181. Romano C, Sesma MA, McDonald CT, et al. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 1995: 355(3): 455-469.
182. Muyderman H, and Ängehagen M, Sandberg M, et al. Alpha 1-Adrenergic modulation of metabotropic glutamate receptor-induced calcium oscillations and glutamate release in astrocytes. J Biol Chem 2001; 276: 46504-46514.
183. Cai Z, Schools GP, Kimelberg HK. Metabotropic glutamate receptors in acutely isolated hippocampal astrocytes: developmental changes of mGluR5 mRNA and functional expression. Glia 2000; 29(1): 70-80.
184. Van den Pol AN, Romano C, Ghosh P. Metabotropic glutamate receptor mGluR5 subcellular distribution and developmental expression in hypothalamus. J Comp Neurol 1995; 362(1): 134-150.
185. Nakahara K, Okada M, Nakanishi S. The metabotropic glutamate receptor mGluR5 induces calcium oscillations in cultured astrocytes via protein kinase C phosphorylation. J Neurochem 1997; 69(4): 1467-1475.
186. Cheng PY, Liu-Chen LY, Pickel VM. Dual ultrastructural immunocytochemical labeling of mu and delta opioid receptors in the superficial layers of the rat cervical spinal cord. Brain Res 1997; 778(2): 367-380.
187. Ruzicka BB, Fox CA, Thompson RC, et al. Primary astroglial cultures derived from several rat brain regions differentially express m, d and k opioid receptor mRNA. Mol Brain Res 1995; 34(2): 209-220.
188. Di Iorio P, Ballerini P, Caciagli F, Ciccarelli R. Purinoceptor-mediated modulation of purine and neurotransmitter release from nervous tissue. Pharmacol Res 1998; 37(3): 169-178.
189. Ciccarelli R, Ballerini P, Sabatino G, et al. Involvement of astrocytes in purine-mediated reparative processes in the brain. Review Int J Dev Neurosci 2001; 19(4): 395-414.
190. Stevens B, Fields RD. Response of Schwann cell to Action potentials in development. Science 2000; 287(5461): 2267-271.
191. Stevens B, Porta S, Haak LL, Gallo V, Fields RD. Adenosine: a neuron-glial transmitter promoting myelination in the CNS in response to action potentials. Neuron 2002; 36(5): 855-868.
192. 2+ signalling in glial cell pathology in the central nervous system. Eur J Pharmacol 2002; 447(2): 247-260.
193. Stevens B, Ishibashi T, Chen JF, Felds, RD. Adenosine: an activity-dependent axonal signal regulating MAP kinase and proliferation in developing Schwann cells. Neuron Glia Biol 2004; 1(1): 23-34.
194. Palma C, Minghetti L, Astolfi M, et al. Functional characterization of substance P receptors on cultured human spinal cord astrocytes: synergism of substance P with cytokines in inducing interleukin-6 and prostaglandin E2 production. Glia 1997; 21(2): 183-193.
195. Tooney PA, Au GG, Chahl LA. Tachykinin NK1 and NK3 Receptors in the Prefrontal Cortex of the Human Brain. Clin Exp Pharmacol Physiol 2000; 27(11): 947-949.
196. Dorf ME, Berman MA, Tanabe S, Heesen M, Luo Y. Astrocytes express functional chemokine receptors. J Neuroimmunol 2000; 111(1-2): 109-121.
197. Bajetto A, Bonavia R, Barbero S, Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem 2002; 82(6): 1311-1329.
198. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci 2006; 27(1): 48-55.
199. Domanska UM, Kruizinga RC, den Dunnenb WFA, et al. The chemokine network, a newly discovered target in high grade gliomas. Crit Rev Oncol Hematol 2011; 79(2): 154-63.
200. Haas AH, Weering HRJ, Jong EK, Boddeke HWGM, Biber KPH. Neuronal chemokines: versatile messengers in central nervous system cell interaction. Mol Neurobiol 2007; 36(2): 137-151.
201. Odemis V, Lipfert J, Kraft R, et al. The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells. Glia 2012; 60(3): 372-381.
202. Mizutani M, Pino PA, Saederup N, et al. The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J Immunol 2012; 188(1): 29-36.